Skip to main content
. 2023 Jun 1;13(6):e072622. doi: 10.1136/bmjopen-2023-072622

Table 1.

Safety outcomes and other predefined outcome measures

No Category Specification Time frame
1 Safety Proportion of children with severe complications during antibiotic treatment, for example, need for intensive care, septic shock, organ failure, pyomyositis, endocarditis, deep venous thrombosis. 28 days
2 Safety Proportion of children with need for surgical intervention during antibiotic treatment. Diagnostic surgical intervention (diagnostic joint aspiration or diagnostic bone biopsy) excluded 28 days
3 Safety Proportion of children with treatment-related adverse events for example, complications of intravenous access (infection, need for replacement, extravasation) and drug side effects reported by medical staff or by parents (electronic questionnaire) 3 months
4 Exploratory Time to apyrexia from initiation of antibiotic treatment 28 days
5 Exploratory Level of mobility and pain assessed by daily grading of symptoms by medical staff and daily standardised pain scores from participants and/or parents. Score systems: Visual Analogue Scale or Face Legs Activity Cry Consolability scale, both with scores from 0 (no pain) to 10 (worst pain). 14 days
6 Exploratory Total duration of antibiotic therapy 3 months
7 Exploratory Proportion of children with sequelae, for example, abnormal mobility and growth abnormalities, assessed by clinical examination by a qualified paediatrician 12 months after the initiation of treatment, accepted range 11–14 months 14 months
8 Exploratory Proportion of children with radiological abnormalities assessed by a qualified radiologist 12 months after initiation of treatment, accepted range 11–14 months 14 months
9 Exploratory Secondary infection with antimicrobial-resistant organisms or Clostridioides difficile 3 months